Intracerebral hemorrhage (ICH) is a neurological condition associated with substantial health challenges and a high rate of morbidity and mortality. Statins have a crucial role in preventing both initial and recurrent cardiovascular and cerebrovascular ischemic events. While the benefits of statins in reducing the risk of ischemic stroke are well-established, some post hoc analyses of studies have raised questions about a potential connection between statin therapy and the development of ICH. This possible increase in the risk of ICH is believed to be related to the direct pharmacological impact of lowering total cholesterol and low-density lipoprotein levels in the bloodstream, along with the additional pleiotropic effects of statins. The Medline, Pubmed, Embase, NCBI, and Cochrane databases were searched for studies of patients with non-alcoholic fatty liver disease. Incidence, etiology, and management options were analyzed. The use of statin therapy in individuals who have experienced a stroke was found to elevate the risk of hemorrhagic stroke, yet it effectively lowered the risk of ischemic strokes. When considering both the advantages and possible drawbacks, statin therapy has an overall positive impact on individuals with a history of stroke or transient ischemic attack (TIA). Nevertheless, further research is necessary to establish the definitive implications of the heightened risk of hemorrhagic stroke that our study has uncovered.